Article

Red Hot Cancer Killing Chili Peppers

Researchers seek to determine how compound from chili peppers kills prostate cancer cells.

Researchers seek to determine how compound from chili peppers kills prostate cancer cells.

A compound derived from chili peppers may eventually by utilized in a new therapeutic form following recent research published in the American Chemical Society’s Journal of Physical Chemistry B.

Investigators evaluated the compound capsaicin, which is responsible for the heat from chili peppers, and is commonly used in pain relieving creams. Additionally, prior studies have found that high doses of capsaicin can kill prostate cancer cells.

For the current study, researchers worked to determine how the substance works. Approximately a decade ago, it was discovered that capsaicin can kill prostate cancer cells in mice without affecting healthy cells.

However, for that dose to translate to treatment in humans it requires eating a huge number of chili peppers each day, the study noted. As a result, investigators sought to evaluate how capsaicin works in order to transform it into an effective drug in injectable or pill form.

The study revealed how the molecule binds to the surface of cells to impact the membrane that surrounds and protects the cell. Researchers determined how the compound interacts with cell membranes by monitoring its natural fluorescence.

The researchers found that capsaicin lodges near surface membranes. In high enough quantities, capsaicin basically causes the membranes to come apart.

Researchers are hopeful that continuing work can eventually lead to the production of new treatments that fight cancer and other conditions.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards